CMS Islet Cell Transplantation Coverage Policy Update: What Billing Teams Need to Know (NCD 286)

CMS has modified National Coverage Determination 286, which governs Medicare coverage for islet cell transplantation in the context of a clinical trial. If your facility participates in NIH-sponsored transplant research or treats Type 1 diabetes patients who may qualify for pancreatic islet cell transplantation, this policy update affects how you document, bill, and verify coverage eligibility. Here's what changed, what's still excluded, and exactly what your revenue cycle team should do next.

What CMS NCD 286 Covers for Islet Cell Transplantation

Under NCD 286, the Centers for Medicare & Medicaid Services covers pancreatic islet cell transplantation—and the full range of associated services—but only when the procedure is performed as part of a National Institutes of Health (NIH)-sponsored clinical trial. This coverage framework was originally established under Section 733 of the Medicare Prescription Drug Improvement and Modernization Act of 2003 (P.L. 108-173), which directed the Secretary of the Department of Health and Human Services to conduct a clinical investigation that includes Medicare beneficiaries.

The covered population is patients with Type 1 diabetes. Islet cell transplantation in this context aims to restore insulin-producing cell function—ideally achieving insulin independence, though improved glucose control and elimination of clinically significant hypoglycemia episodes are also recognized as important patient outcomes.

Medicare covers the following services under NCD 286 when rendered within a qualifying NIH-sponsored trial:

• Acquisition and delivery of pancreatic islet cells (typically requiring over 500,000 islet cells, though volume varies by recipient weight)
• The transplantation procedure itself, which involves injection into the portal vein via direct visualization, guided ultrasound, or percutaneous approach
• Clinically necessary inpatient and outpatient medical care
• Immunosuppressant drugs (required to prevent rejection of transplanted islet cells)
• Routine follow-up care for trial participants

Coverage extends to islet cell transplant performed alone, in combination with a kidney transplant, or following a prior kidney transplant. The term "routine costs" is defined in section 310.1 of the NCD Manual and encompasses reasonable and necessary routine patient care costs.

The applicable benefit categories are Inpatient Hospital Services and Physicians' Services.

What CMS Explicitly Does Not Cover Under NCD 286

This is the critical non-coverage distinction your billing team needs to internalize before submitting any claim.

Partial pancreatic tissue transplantation is not covered under any circumstances. Islet cell transplantation performed outside the context of a clinical trial is also explicitly noncovered—even when the procedure is otherwise clinically appropriate for a Type 1 diabetes patient. There are no exceptions or pathways to coverage for islet cell transplantation performed in a standard clinical setting without active NIH trial enrollment.

This means a patient who meets the clinical profile—Type 1 diabetes, recurrent hypoglycemia, failed conventional management—is still not a covered candidate unless they are enrolled in a qualifying NIH-sponsored trial. Billing Medicare for islet cell transplantation outside that trial context will result in denial and may raise compliance concerns.

Clinical Context: How the Procedure Works

Understanding the clinical workflow helps billing teams ask the right questions during pre-registration and prior to claim submission.

One or more donor pancreata are procured, and islets must be extracted within hours of pancreas recovery to maintain viability. That narrow window creates logistical complexity—including coordination between procurement, processing, and transplant teams—that generates billable services across multiple departments and providers.

The islet cells are then injected into the recipient's portal vein. Depending on the approach used (direct visualization, ultrasound guidance, or percutaneous), the interventional radiology team may be involved, which means separate professional and facility claims may be generated from a single transplant encounter.

Post-transplant, immunosuppressant therapy is ongoing. These drugs are coverable under NCD 286 as part of routine costs—but again, only within the clinical trial context. Document the trial affiliation at every follow-up encounter.

Affected Codes

This policy does not list specific CPT or HCPCS codes. CMS has not assigned procedure-specific codes within NCD 286 itself. Billing teams should consult claims processing guidance directly—specifically:

• Transmittal 261 (Claims Processing Manual)
• Transmittal 986 (Medicare Claims Processing)

These transmittals contain the applicable claims processing instructions for islet cell transplantation services under this NCD. Work with your coding team and MAC (Medicare Administrative Contractor) to confirm current code assignments, as coding for transplant services can involve multiple CPT ranges covering procurement, transplantation, and follow-up management.

There are no ICD-10-CM codes specified within this NCD document.

What Your Billing Team Should Do